腹腔镜HIPEC治疗胃癌的II期临床试验经验总结
该II期临床试验旨在评估新辅助腹腔镜HIPEC(不联合细胞减灭术)用于胃癌腹膜阳性细胞学或低体积腹膜癌患者的安全性与可行性,患者完成全身化疗后接受最多5次腹腔镜HIPEC,若腹膜病变完全缓解则行胃切除术。视频展示了19例患者共38次腹腔镜HIPEC的技术细节及手术经验。
要点
- 腹腔镜HIPEC采用丝裂霉素C 30mg联合顺铂200mg,灌注液3-7L,流速700-1500mL/min,循环60分钟。
- 腹腔镜HIPEC最多可重复5次,作为新辅助治疗用于胃癌腹膜阳性细胞学或隐匿性腹膜癌患者。
- 腹膜外病变完全缓解的患者随后接受胃切除术。
核心结论
- 腹腔镜新辅助HIPEC不联合细胞减灭术在胃癌腹膜阳性细胞学或低体积腹膜癌患者中技术可行,可为后续胃切除术创造条件。
研究设计与样本
- II期临床试验(NCT02092298),纳入胃或胃食管腺癌伴腹膜阳性细胞学或影像学隐匿性腹膜癌且已完成全身化疗的患者。
- 共19例患者接受了38次腹腔镜HIPEC操作。
主要发现
- 腹腔镜HIPEC采用丝裂霉素C 30mg和顺铂200mg溶于3-7L灌注液,体外循环装置流速700-1500mL/min,循环60分钟。
- 腹腔镜HIPEC最多可进行5次。
- 腹膜外病变完全缓解的患者成为胃切除术的候选者。
关键数值与推荐
- 腹腔镜HIPEC药物方案:丝裂霉素C 30mg,顺铂200mg。
- 灌注液容量3-7L,流速700-1500 mL/min,循环时间60分钟。
- 腹腔镜HIPEC最多重复5次。
临床怎么用
- 对于胃癌腹膜阳性细胞学或低体积腹膜癌患者,可考虑新辅助腹腔镜HIPEC而不联合细胞减灭术。
- 完成全身化疗后评估腹膜病变缓解情况,完全缓解者可行胃切除术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) for patients with gastric cancer and positive cytology or carcinomatosis. The morbidity and mortality rates of cytoreduction and HIPEC, in combination with gastrectomy, are significant and the survival rates of this approach may not extend beyond that of treatment with systemic chemotherapy. The objective of this clinical trial, therefore, was to perform HIPEC in a neoadjuvant fashion via a minimally invasive approach without cytoreduction for patients with gastric cancer and positive cytology or low volume carcinomatosis. Patients found to have resolution of all extra-gastric disease are then candidates for gastrectomy. METHODS: Patients with gastric and gastroesophageal adenocarcinoma and positive peritoneal cytology or radiologically-occult carcinomatosis that have completed treatment with systemic chemotherapy were offered participation in the study. RESULTS: We have performed 38 laparoscopic HIPEC procedures in 19 patients. Laparoscopic HIPEC consists of Mitomycin C 30 mg and Cisplatin 200 mg in 3-7 L of infusate circulated using an extracorporeal circulation device at a flow rate of 700-1500 mL/minute for 60 min. The Laparoscopic HIPEC procedure may be performed up to five times. In this video, we sought to present the surgical technique refined during our development and completion of this Phase II clinical trial (NCT02092298). CONCLUSION: The purpose of this presentation is to (1) demonstrate the technique of laparoscopic HIPEC and (2) review the surgical lessons learned from performing multiple HIPEC procedures prior to attempted gastrectomy.
引用
- Badgwell B, Blum M, Das P, et al. Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. Surg Endosc. 2017. PMID: 28643069. doi:10.1007/s00464-017-5668-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。